Kensinger Clark, Karp Seth, Kant Rishi, Chui Benjamin W, Goldman Kenneth, Yeager Torin, Gould Edward R, Buck Amanda, Laneve David C, Groszek Joseph J, Roy Shuvo, Fissell William H
From the *Department of Surgery, Vanderbilt University, Nashville, Tennessee; †Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California; ‡Ben Chui Consulting, Sunnyvale, California; §H-Cubed, Inc., Olmsted Falls, Ohio; Departments of ¶Nephrology and Hypertension, ‖Surgery, #Radiology and Radiological Sciences, and **Biomedical Engineering, Vanderbilt University, Nashville, Tennessee.
ASAIO J. 2016 Jul-Aug;62(4):491-5. doi: 10.1097/MAT.0000000000000367.
An implantable hemofilter for the treatment of kidney failure depends critically on the transport characteristics of the membrane and the biocompatibility of the membrane, cartridge, and blood conduits. A novel membrane with slit-shaped pores optimizes the trade-off between permeability and selectivity, enabling implanted therapy. Sustained (3-8) day function of an implanted parallel-plate hemofilter with minimal anticoagulation was achieved by considering biocompatibility at the subnanometer scale of chemical interactions and the millimeter scale of blood fluid dynamics. A total of 400 nm-thick polysilicon flat sheet membranes with 5-8 nm × 2 micron slit-shaped pores were surface-modified with polyethylene glycol. Hemofilter cartridge geometries were refined based on computational fluid dynamics models of blood flow. In an uncontrolled pilot study, silicon filters were implanted in six class A dogs. Cartridges were connected to the cardiovascular system by anastamoses to the aorta and inferior vena cava and filtrate was drained to collection pouches positioned in the peritoneum. Pain medicine and acetylsalicylic acid were administered twice daily until the hemofilters were harvested on postoperative days 3 (n = 2), 4 (n = 2), 5 (n = 1), and 8 (n = 1). No hemofilters were thrombosed. Animals treated for 5 and 8 days had microscopic fractures in the silicon nanopore membranes and 20-50 ml of transudative (albumin sieving coefficient θalb ~ 0.5 - 0.7) fluid in the collection pouches at the time of explant. Shorter experimental durations (3-4 days) resulted in filtration volumes similar to predictions based on mean arterial pressures and membrane hydraulic permeability and (θalb ~ 0.2 - 0.3), similar to preimplantation measurements. In conclusion, a detailed mechanistic and materials science attention to blood-material interactions allows implanted hemofilters to resist thrombosis. Additional testing is needed to determine optimal membrane characteristics and identify limiting factors in long-term implantation.
一种用于治疗肾衰竭的可植入血液滤过器,其性能关键取决于膜的传输特性以及膜、滤筒和血液导管的生物相容性。一种具有狭缝形孔的新型膜优化了渗透性和选择性之间的权衡,从而实现植入式治疗。通过在化学相互作用的亚纳米尺度和血液流体动力学的毫米尺度上考虑生物相容性,实现了植入式平行板血液滤过器在最小抗凝情况下持续(3 - 8)天的功能。对总共400纳米厚、具有5 - 8纳米×2微米狭缝形孔的多晶硅平板膜进行了聚乙二醇表面改性。基于血流的计算流体动力学模型对血液滤过器滤筒的几何形状进行了优化。在一项非对照的初步研究中,将硅滤器植入6只A类犬体内。滤筒通过与主动脉和下腔静脉的吻合连接到心血管系统,滤液引流到位于腹膜内的收集袋中。每天两次给予止痛药和乙酰水杨酸,直到在术后第3天(n = 2)、第4天(n = 2)、第5天(n = 1)和第8天(n = 1)取出血液滤过器。没有血液滤过器发生血栓形成。接受治疗5天和8天的动物,其硅纳米孔膜出现微观破裂,取出时收集袋中有20 - 50毫升渗出液(白蛋白筛分系数θalb约为0.5 - 0.7)。较短的实验持续时间(3 - 4天)导致过滤体积与基于平均动脉压和膜水力渗透率的预测值相似(θalb约为0.2 - 0.3),与植入前测量值相似。总之,对血液 - 材料相互作用给予详细的机理和材料科学关注,可使植入式血液滤过器抵抗血栓形成。需要进行额外测试以确定最佳膜特性并识别长期植入中的限制因素。